Level 2

Oxford Biomedica CEO John Dawson to step down

By Frank Prenesti

Date: Monday 17 Jan 2022

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.
Dawson said he would "retire at the appropriate time".

"I believe this is the right time to start the transition to a new leader given the robustness of the senior team and company as a whole, which is undoubtedly stronger than ever before," he said in a statement.

Oxford Biomedica chairman Dr Roch Doliveux said it had started searching for Dawson's replacement to "lead the group through its next phase of growth".


Email this article to a friend

or share it with one of these popular networks:

Top of Page